submit to the journals

EHA Highlights

flipper_slider

Editor's Choice

Paul Richardson from the Dana-Farber Cancer Institute and Harvard Medical School provides an overview of the key findings of the OPTIMISMM trial and discusses the need for new treatment strategies in multiple...

EHA Highlights Videos

touchONCOLOGY talks to Arnon P Kater from the Academisch Medisch Centrum Universiteit van Amsterdam about the MURANO study and the impact of TP53-mutated clone size on outcome of relapsed/refractory (R/R) CLL patients treated with venetoclax plus rituximab. 1. Why do chronic lymphocytic...
Annalisa Chiapella from Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino in Italy talks to touchONCOLOGY about patients with diffuse large B-cell lymphoma (DLBCL) with a TP53 mutation, and the aims and findings of the FIL-DLCL04 study to help tackle this. 1...
Martin Hutchings from Copenhagen University Hospital discusses the ECHELON-1 trial and treatment strategies in Hodgkin's lymphoma. 1. What are the limitations of current ABVD chemotherapy regimes for advanced Hodgkin’s lymphoma? (0:10) 2. Could you tell us a little about the ECHELON-1...
Paul Richardson from the Dana-Farber Cancer Institute and Harvard Medical School provides an overview of the key findings of the OPTIMISMM trial and discusses the need for new treatment strategies in multiple myeloma. 1. Why is there a need for new combinations of therapies in relapsed/...
We catch up with editorial board member Willem Fibbe from Leiden University Medical Centre to discuss mesenchymal stromal cells and their therapeutic potential in the clinic. 1. What properties of mesenchymal stromal cells (MSCs) have led to the investigation of their therapeutic...
Muzaffar Qazilbash from The University of Texas MD Anderson Cancer Center talks to touchONCOLOGY about investigating busulfan plus melphalan as a potential combination therapy for high-risk multiple myeloma. 1. What was the rationale for using a combined busulfan and melphalan...
Maria Cappellini discusses Gaucher disease and the consequences of late diagnosis. FILMED AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) ANNUAL MEETING, JUNE 2016 CAN YOU TELL US SOMETHING ABOUT GAUCHER DISEASE AND THE CONSEQUENCES OF NOT DIAGNOSING IT EARLY? 00:10 – Gaucher disease is a...
Christian Buske discusses Waldenström’s macroglobulinemia and the aims and findings of the pan-European data platform. FILMED AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) ANNUAL MEETING, JUNE 2016 WHAT IS WALDENSTRÖM’S MACROGLOBULINEMIA (WM)? 00:10 – Waldenström’s Macroglobulinemia belongs...
Ruben Mesa talks about the clinical assessments involved in identifying inadequately controlled polycythemia vera (PV), and discusses strategies to help to improve the quality of life of patients with PV. Disclosures: Ruben Mesa is a consultant to Novartis, Ariad and Galena, and has received...
Michele Baccarani discusses the factors influencing the decision to switch tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukaemia and the options available for patients who develop the T315I "gatekeeper" mutation. Disclosures: Michele Baccarani has received honoraria from ARIAD,...
Mareike Aichholzer discusses her poster presentation on the comprehensive monitoring of gut microbiota during therapy for acute leukaemia. FILMED AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) ANNUAL MEETING, JUNE 2016 WHAT IS THE IMPACT ON THE GUT MICROBIOTA ON TREATMENT RESPONSE IN ACUTE...
Andrew Spencer discusses the role ofhistone deacetylase (HDAC) inhibition in multiple myeloma and what we need to understand better to explore the further potential of HDAC inhibition. FILMED AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) ANNUAL MEETING, JUNE 2016 WHY IS HISTONE DEACETYLASE (...
Nicolaus Kroeger discusses the phase III study for the prevention of chronic graft-versus-host disease published earlier this year, and the ongoing research to further explore the role of anti T-lymphocyte globulin. FILMED AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) ANNUAL MEETING, JUNE 2016...
Christian Gisselbrecht explains the key findings of the SCHOLAR-1 study and the ongoing research to address the unmet need in the treatment of refractory aggressive diffuse large B-cell lymphoma (DLBC) FILMED AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) ANNUAL MEETING, JUNE 2016 WHAT ARE THE...
Neils Weinhold talks about the diagnostic challenges posed by tumour heterogeneity in multiple myeloma and the impact of this heterogeneity on targeted treatment. FILMED AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) ANNUAL MEETING, JUNE 2016 WHAT IS THE LEVEL OF SPATIAL HETEROGENEITY IN...